Pros | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. | - |
INDMoney rank | 7/8 | 2/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 12 Years | ||
Fund Size | 8357 Cr | 3933 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 0.89% | 0.91% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 41 | 34 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.94%) Divi's Laboratories Ltd (7.34%) Cipla Ltd (6.09%) Lupin Ltd (6.09%) Apollo Hospitals Enterprise Ltd (5.91%) | Sun Pharmaceuticals Industries Ltd (10.86%) Divi's Laboratories Ltd (6.81%) Max Healthcare Institute Ltd Ordinary Shares (6.12%) Cipla Ltd (4.81%) Lonza Group Ltd ADR (4.24%) | ||
No of Sectors | 1 | 3 | ||
Top 3 Sectors | Health (100%) | Health (93.98%) Basic Materials (6.02%) Government (1.7%) | ||
Equity % | 99.48% | 96.15% | ||
Debt % | - | - | ||
P/E | 36.11 | 43.78 | ||
P/B | 5.78 | 6.26 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -0.45% | -0.03% | ||
3-Month Return | -0.25% | 0.41% | ||
6-Month Return | 11.51% | 10.68% | ||
1-Year Return | -1.02% | 4.34% | ||
3-Year Return | 22.76% | 26.76% | ||
5-Year Return | 17.96% | 20.12% |
Sharpe | 0.95 | 1.25 | ||
Alpha | -0.12 | 4.15 | ||
Beta | 0.91 | 0.84 | ||
Standard Deviation | 15.23 | 14.09 | ||
Information Ratio | -0.44 | 0.6 |
Description | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Sailesh Raj Bhan,Kinjal Desai | Tanmaya Desai |